This is a 17-week double-blind, placebo-controlled, randomized, flexible-dosing, parallel-group, multicenter study designed to evaluate the efficacy and safety of suvecaltamide for the treatment of moderate to severe residual tremor in adult participants with Parkinson's disease (PD). The target population represents participants who have tremor that is not adequately controlled by PD medications and that interferes with their activities of daily living (ADL) and/or with their performance of tasks.
1 Primary · 8 Secondary · Reporting Duration: Week 17 post-dose.
160 Total Participants · 2 Treatment Groups
Primary Treatment: Sulvecaltamide · Has Placebo Group · Phase 2
Age 40 - 80 · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: